ObjectiveTo systematically review the prediction models of blood-based biomarkers for non-small cell lung cancer (NSCLC). MethodsThe PubMed, Embase, Cochrane Library, Web of Science, VIP, WanFang Data and CNKI databases were electronically searched to collect studies related to the objectives from inception to June, 2023. Two reviewers independently screened literature, extracted data and assessed the risk of bias of the included studies. Meta-analysis was then performed by using RevMan 5.4.1 software. ResultsA total of 8 studies were included and all of them were retrospective cohort studies. The models were internally validated in 2 studies and externally validated in 4 studies. The performances of the eight predictive models were stable, which was measured by the area under the curve of receiver operating characteristic curve lying between 0.664 and 0.783. However, the risk of bias was high, which may mainly be reflected in data processing, model validation and performance adjustment. Meta-analysis showed that LDH (HR=1.86, 95%CI 41.32 to 2.63, P<0.01), dNLR (HR=2.15, 95%CI 1.56 to 2.96, P<0.01) and NLR (HR=1.71, 95%CI 1.08 to 2.69, P=0.02) were independent factors of prognosis for NSCLC patients. Conclusion Current evidence shows that the NSCLC prediction models based on peripheral blood biomarkers are still in the development stage, and the models have a high risk of bias.